J
Jeffrey L. Brown
Researcher at AstraZeneca
Publications - 31
Citations - 1826
Jeffrey L. Brown is an academic researcher from AstraZeneca. The author has contributed to research in topics: Cancer & Trk receptor. The author has an hindex of 16, co-authored 30 publications receiving 1550 citations.
Papers
More filters
Journal ArticleDOI
Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
Roberta Mazzieri,Ferdinando Pucci,Davide Moi,Erika Zonari,Anna Ranghetti,Alvise Berti,Letterio S. Politi,Bernhard Gentner,Jeffrey L. Brown,Luigi Naldini,Michele De Palma +10 more
TL;DR: Blocking angiopoietin-2 (ANG2), a TIE2 ligand and angiogenic factor expressed by activated endothelial cells (ECs), regresses the tumor vasculature and inhibits progression of late-stage, metastatic MMTV-PyMT mammary carcinomas and RIP1-Tag2 pancreatic insulinomas.
Journal ArticleDOI
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells
Marwan Kwok,Marwan Kwok,Nicholas J. Davies,Angelo Agathanggelou,Edward Smith,Ceri E. Oldreive,Eva Petermann,Grant S. Stewart,Jeffrey L. Brown,Alan Lau,Guy Pratt,Helen Parry,Helen Parry,Malcolm Taylor,Paul Moss,Paul Moss,Peter Hillmen,Tatjana Stankovic,Tatjana Stankovic +18 more
TL;DR: In TP53- or ATM-defective CLL cells, inhibition of ATR signaling by AZD6738 led to an accumulation of unrepaired DNA damage, which was carried through into mitosis because of defective cell cycle checkpoints, resulting in cell death by mitotic catastrophe.
Journal ArticleDOI
A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models
Jeffrey L. Brown,Z. Alexander Cao,Maria C. Pinzon-Ortiz,Jane Kendrew,Corinne L. Reimer,Shenghua Wen,Joe Q. Zhou,Mohammad Tabrizi,Steve Emery,Brenda McDermott,Lourdes Pablo,Patricia Mccoon,Vahe Bedian,David C. Blakey +13 more
TL;DR: These studies provide preclinical data for 3.19.3 as a potential new antiangiogenic therapy as a single agent or in combination with chemotherapy or vascular endothelial growth factor inhibitors for the treatment of cancer.
Journal ArticleDOI
AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.
Ahrum Min,Ahrum Min,Seock-Ah Im,Seock-Ah Im,Seock-Ah Im,Hyemin Jang,Seongyeong Kim,Miso Lee,Debora Keunyoung Kim,Yaewon Yang,Yaewon Yang,Hee Jun Kim,Hee Jun Kim,Kyung Hun Lee,Kyung Hun Lee,Kyung Hun Lee,Jin Won Kim,Jin Won Kim,Tae Yong Kim,Tae Yong Kim,Tae Yong Kim,Do Youn Oh,Do Youn Oh,Do Youn Oh,Jeffrey L. Brown,Alan Lau,Mark J. O'Connor,Yung-Jue Bang,Yung-Jue Bang,Yung-Jue Bang +29 more
TL;DR: Investigation of the potential use of the ATR inhibitor, AZD6738, to treat gastric cancer found it significantly suppressed tumor growth and increased apoptosis in an in vivo tumor xenograft mouse model, suggesting synthetic lethality between ATR inhibition and ATM deficiency in Gastric cancer cells.
Journal ArticleDOI
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
Teeru Bihani,Hitisha K. Patel,Heike Arlt,Nianjun Tao,Hai Jiang,Jeffrey L. Brown,D Purandare,Gary Hattersley,F Garner +8 more
TL;DR: Elacestrant induces the degradation of ER, inhibits ER-mediated signaling and growth of ER+ breast cancer cell lines in vitro and in vivo, and significantly inhibits tumor growth of multiple PDX models, highlighting the potential clinical utility of elacestant as a single agent and as a combination therapy, for both early- and late-stage ER+ disease.